Je kunt je niet meer inschrijven voor dit webinar

Malaria is a deadly disease that affected over 240 million people in 2020, an increase over progress in previous years. Despite advances in malariology, the challenge of finding the right drugs to treat the illness is complex. 
During this hourlong webinar, drug discovery experts Dr James Duffy (Medicines for Malaria Ventures (MMV)), Dr Koen Dechering (TropIQ) and Martijn Timmerman (Pivot Park Screening Center (PPSC)) will share: 
  • perspectives and strategies in antimalaria drug discovery  
  • the biology of the malaria models  
  • small molecule tactics and technical assay development  
  • a novel transgenic malaria reporter strain with excellent performance in high-throughput screening  
  • screening and hit generation of active compounds against the blood stage of the Plasmodium falciparum parasite 
  • triage of large compound libraries screening 
Join this webinar on 22 June at 16.00 p.m. (CEST) 

Duration
Presentation: 60 minutes (16:00 hrs. CET)
You can view this webinar from your computer, tablet or mobile phone.

​About the presenters:
Dr James Duffy, Director of Drug Discovery, Medicines for Malaria Venture (MMV) 
James Duffy is a Director of Drug Discovery at Medicines for Malaria Venture (MMV) with 21 years’ experience working in drug discovery. He has a special interest in malaria and other infectious diseases that disproportionately affect vulnerable populations. 
 
Dr Koen Dechering, CEO, TropIQ Health Sciences 
Koen Dechering pioneered the study of gene regulation during sexual development of malaria parasites and received his PhD in 1998. In 2011, Koen founded TropIQ Health Sciences with the aim of accelerating the development of novel therapies against tropical infectious diseases. 

Martijn Timmerman, scientist, Pivot Park Screening Centre 
Martijn Timmerman is a scientist at Pivot Park Screening Centre with many years of experience in the validation and automation of high-throughput assays. He joined PPSC almost 10 years ago and performed numerous screening campaigns. 


Share this webinar